Navigation Links
Phase III data show efficacy/safety of iclaprim in patients with complicated skin infections
Date:10/27/2008

Reinach, Switzerland, 26 October 2008 Arpida (SWX: ARPN) today presented the combined results from two pivotal Phase III clinical trials at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th annual meeting in Washington, DC. In these studies, intravenous iclaprim, a novel antibiotic, showed high clinical cure rates which were similar to those of the comparator drug, linezolid, in the treatment of complicated skin and skin structure infections (cSSSI) caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). In addition, iclaprim was well-tolerated with a safety profile that compared favorably to linezolid. A New Drug Application for intravenous iclaprim in cSSSI will be discussed at the meeting of the U.S. Food and Drug Administration Anti-Infective Drugs Advisory Committee on 20 November 2008.

Iclaprim, a novel antibiotic from the trusted dihydrofolate reductase (DHFR) selective inhibitor class of antibiotics, was specifically designed to address the growing need for additional treatment options to combat resistant infections including MRSA. MRSA affects more than 2 million people in the United States each year and rates of hospital- and community-acquired MRSA are on the rise. ,

"The high efficacy rates and favorable tolerability profile of iclaprim strongly supports its potential as a new treatment option for patients who have acquired serious infections caused by MRSA," said Dennis L. Stevens, MD, PhD, Veterans Affairs Medical Center, Boise, Idaho. "With rates of MRSA increasing and effectiveness of some current antibiotics declining, it is important to identify effective alternative treatments for these infections."

The results presented at the ICAAC/IDSA meeting were gathered from the ASSIST-1 and ASSIST-2, (Arpida's Skin and Skin Structure Infection STudy) pivotal Phase III studies involving a total of 991
'/>"/>

Contact: Dr. Jrgen Raths
41-614-179-660
Zeno Group
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. PTC124 shows activity in cystic fibrosis; Phase 2 proof-of-concept data published in Lancet
2. Improved foam for varicose veins found to be safe in preliminary results from phase II trial
3. Moms obesity during conception phase may set the stage for offsprings obesity risk
4. Liquid crystal phases of tiny DNA molecules point up new scenario for first life on Earth
5. HGS announces positive Phase 2 LymphoStat-B at ACR meeting
6. Phase 2 of Singapores Biomedical Sciences Initiative gains momentum for clinical research
7. CABI helps phase out dangerous pesticide in EU
8. SinuNase Phase 3 show almost 100 percent of chronic sinusitis cases are from fungal-induced inflamma
9. New test promises quicker, more accurate evaluation for cystic fibrosis patients
10. How eating fruit and vegetables can improve cancer patients response to chemotherapy
11. UCSF Fresno leading-edge study lends hope to emphysema patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... purified crystals that split light with uncanny precision ... and, potentially, computers that manipulate light instead of ... such as etching them with a precise beam ... , Now, researchers at Princeton and Columbia universities ... scientists to customize and grow these specialized materials, ...
(Date:7/22/2014)... milk helps make their bones strong or that fish is food ... if something is good for us, it must surely taste bad? ... Research , when children hear about the benefits of healthy food, ... food is presented to children as making them strong or as ... read or count, they would conclude the food is not as ...
(Date:7/22/2014)... trees and not just asphalt and recreation equipment reduces ... Colorado Boulder study. , Working on class assignments or ... youth, according to a paper published in the journal ... of the first of its kind to focus on ... stress. , "Many schools already offer stress management programs, ...
Breaking Biology News(10 mins):Technique simplifies the creation of high-tech crystals 2Technique simplifies the creation of high-tech crystals 3Natural-terrain schoolyards reduce children's stress, says Colorado University-Boulder study 2Natural-terrain schoolyards reduce children's stress, says Colorado University-Boulder study 3
... of Medicine (BUSM) have demonstrated that certain T cells ... pro-inflammatory response in people with type 2 diabetes (T2D). ... a loss in homeostasis in this group of T ... Barbara Nikolajczyk, PhD, an associate professor of ...
... the winners of its international travel grants to ... the Baltimore Convention Center in Baltimore, Maryland, March ... is to foster and initiate further interaction between ... financial difficulties. Recipients of this competitive award ...
... rap as vermin and pests because they seem to thrive ... in Africa for the past 50 million years. From ... a stable and plentiful source of food, says paleontologist Alisa ... fossils are proving their usefulness to scientists as they help ...
Cached Biology News:Biophysical Society announces winners of 2011 International Travel Awards 2Biophysical Society announces winners of 2011 International Travel Awards 3Biophysical Society announces winners of 2011 International Travel Awards 4Rodents were diverse and abundant in prehistoric Africa when our human ancestors evolved 2Rodents were diverse and abundant in prehistoric Africa when our human ancestors evolved 3
(Date:7/22/2014)... Parsippany, NJ (PRWEB) July 22, 2014 ... analytical, precision, portable, and mechanical balances and scales, ... precision balances has won Laboratory Equipment magazine’s 2014 ... is the second consecutive year the Explorer was ... readers. The annual Readers’ Choice Awards celebrates “excellence ...
(Date:7/22/2014)... and SHENZHEN, China , ... Co., LTD, (BGI Tech), a subsidiary of BGI, ... global launch of a new human whole exome ... This newly offered service includes in-depth bioinformatics analysis ... prices until December 31, 2014. ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Quorum Review IRB, ... service for large clinical trials called Quick Step™ . ... designed to address the research industry’s need for seamless study ... service is available for studies planning 50 or more North ... combined planned North American site count of 80 or more. ...
(Date:7/22/2014)... 2014 The next session of ... and will comprise of the increasingly popular ‘Base SAS’ ... is a series of technical hands-on classes for entry-level ... reach the next step in their professional careers. , ... by Jennifer Kang, Senior Statistician at Genentech and former ...
Breaking Biology Technology:OHAUS Explorer Voted “Best Balance” in Laboratory Equipment’s 2014 Readers’ Choice Awards 2BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 2BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 3Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 2Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 3Clinovo TechTrainings: Next Session of SAS and CDISC Classes Start 9th September, 2014 2Clinovo TechTrainings: Next Session of SAS and CDISC Classes Start 9th September, 2014 3
... March 21, 2011 Cell Therapeutics, Inc. ("CTI") (Nasdaq ... its randomized pivotal trial of pixantrone for the treatment ... trial is now open to patient enrollment. The trial, ... will compare a combination of pixantrone plus rituximab to ...
... 18, 2011 Driving value for customers is critical to ... points between a customer and an organization, there has to ... an organization to succeed in the marketplace. ... Practices, LLC., noted in this month,s special issue of PharmaVoice ...
... 2011 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... Approach for PKU Treatment) in an abstract (Abstract #91 ... presented by Barbara Burton, MD at the 2011 annual ... Canada.  ADAPT, which was funded by a grant from ...
Cached Biology Technology:Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma 2Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma 3Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma 4Best Practices, LLC Showcases Its Expertise in Customer Relationship Management 2First-of-Its-Kind Study Suggests Importance of Routine Mental Health Screening in the Care of Patients Suffering From Genetic Disease PKU 2First-of-Its-Kind Study Suggests Importance of Routine Mental Health Screening in the Care of Patients Suffering From Genetic Disease PKU 3First-of-Its-Kind Study Suggests Importance of Routine Mental Health Screening in the Care of Patients Suffering From Genetic Disease PKU 4First-of-Its-Kind Study Suggests Importance of Routine Mental Health Screening in the Care of Patients Suffering From Genetic Disease PKU 5First-of-Its-Kind Study Suggests Importance of Routine Mental Health Screening in the Care of Patients Suffering From Genetic Disease PKU 6First-of-Its-Kind Study Suggests Importance of Routine Mental Health Screening in the Care of Patients Suffering From Genetic Disease PKU 7First-of-Its-Kind Study Suggests Importance of Routine Mental Health Screening in the Care of Patients Suffering From Genetic Disease PKU 8